Recently a program at Mount Sinai noted the emergence of rare blood cancers among 9/11 first responders. (discovermagazine.com)
The Learning Collaborative (TLC) is a dedicated collaboration between the NIH Chemical Genomics Center (NCGC) and its Therapeutics for Rare and Neglected Diseases (TRND) program, The Leukemia & Lymphoma Society (LLS), and KUCC to discover and develop new drug therapies for rare blood cancers. (cancerres.aacrjournals.org)
The biotech received Food and Drug Administration (FDA) approval for its drug to treat the rare blood cancer acute myeloid lymphoma (AML), which will be marketed as Idhifa, on Tuesday. (fortune.com)